VBI Vaccines (NASDAQ:VBIV) posted its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.02), MarketWatch Earnings reports. The company had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.24 million. VBI Vaccines had a negative net margin of 6,175.95% and a negative return on equity of 53.12%.
NASDAQ VBIV traded down $0.12 during trading on Friday, hitting $2.05. 350,317 shares of the company’s stock traded hands, compared to its average volume of 285,258. VBI Vaccines has a 12-month low of $1.64 and a 12-month high of $5.10. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 0.14.
Several equities research analysts have commented on the stock. Zacks Investment Research downgraded shares of VBI Vaccines from a “hold” rating to a “sell” rating in a report on Friday, September 28th. BMO Capital Markets dropped their price objective on shares of VBI Vaccines from $13.00 to $12.00 and set an “outperform” rating on the stock in a report on Friday, July 27th. Finally, ValuEngine raised shares of VBI Vaccines from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Two analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $8.63.
TRADEMARK VIOLATION NOTICE: This report was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/11/10/vbi-vaccines-vbiv-issues-quarterly-earnings-results-misses-estimates-by-0-02-eps.html.
VBI Vaccines Company Profile
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
See Also: What does earnings per share mean?
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.